Market News AIOpen the app

GLUE stock news · Monte Rosa Therapeutics, Inc.

Stories about Monte Rosa Therapeutics, Inc. (GLUE) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for GLUE

Follow Monte Rosa Therapeutics, Inc. (GLUE) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for GLUE
Free on the App Store and Google Play, or on the web.
  1. Oct 1, 2026, 12:53 PM ET · Market

    Monte Rosa Therapeutics' new drug might help people with heart disease.

    Good for GLUE

    Monte Rosa reported large drops in several inflammation markers with MRT-8102 and plans 3 Phase 2 studies. The early results favor the company, but do not show fewer heart problems.

  2. Oct 1, 2026, 8:15 AM ET · Market

    12 health care stocks are changing a lot before the market opens on Thursday.

    Neutral

    Monte Rosa Therapeutics shares rose 8.13%. The article reports a share move, not business news that changes the company's outlook.

  3. Oct 1, 2026, 7:41 AM ET · Market

    Monte Rosa Therapeutics, Inc. says it has good news about its MRT-8102 study results.

    Good for GLUE

    Monte Rosa said MRT-8102 lowered inflammation-related blood and plaque signs in a Phase 1 study. The early findings support more testing, but do not show fewer heart attacks.

  4. Oct 1, 2026, 6:39 AM ET · Market

    GLUE stock jumps more than 20% before the market opens: What’s causing the rise?

    Neutral

    Monte Rosa plans to discuss its MRT-8102 Phase 1 study results, but this story reports no findings. It therefore does not change the company's outlook.

  5. Sep 30, 2026, 5:30 PM ET · Market

    12 health care stocks are changing in price during Wednesday's after-hours trading.

    Neutral

    Monte Rosa Therapeutics shares rose 9.7% after hours, but the story reports no company news. That move alone does not change the company's outlook.